Logo Logo Logo Logo Logo
  • About
    • Board & Management
    • Business Development
  • Diagnostic Areas
    • COVID-19
    • Intelligent Innovation
  • Products & Solutions
    • Near-patient Workflow Solutions
  • News
  • Investors
    • Year in Review 2021
    • Corporate Calendar
    • Financial Reports
    • Leadership
    • General Meetings
    • Other Regulated Information
    • Advisor and Investor Contacts
    • AIM Rule 26 information
    • Corporate Governance
  • Our People
    • Careers
  • Contact
  • English
    • French
  • About
    • Board & Management
    • Business Development
  • Diagnostic Areas
    • COVID-19
    • Intelligent Innovation
  • Products & Solutions
    • Near-patient Workflow Solutions
  • News
  • Investors
    • Year in Review 2021
    • Corporate Calendar
    • Financial Reports
    • Leadership
    • General Meetings
    • Other Regulated Information
    • Advisor and Investor Contacts
    • AIM Rule 26 information
    • Corporate Governance
  • Our People
    • Careers
  • Contact
  • English
    • French
Search:

02 Jun Coronavirus update Sales and regulatory update

Posted at 07:00h in Board, Novacyt Group, Products

Paris, France and Camberley, UK – 2 June 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction...

Read More

01 Jun Liquidity Agreement Monthly Update and Total Voting Rights

Posted at 06:37h in Board, Novacyt Group, Products

Paris, France and Camberley, UK – 1 June 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded...

Read More

14 May Final results for the year ended 31 December 2019 and outlook for 2020

Posted at 07:17h in Board

Paris, France and Camberley, UK – 14 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its audited final results for the year...

Read More

04 May Liquidity Agreement Monthly Update and Total Voting Rights

Posted at 14:36h in Products

Paris, France and Camberley, UK – 4 May 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded...

Read More

03 May Participations des Administrateurs / PERD

Posted at 15:21h in Uncategorized

https://novacyt.com/wp-content/uploads/2020/12/27-Novacyt-Directors-Dealings-RNS-FRENCH-18.05.2020.pdf ...

Read More

29 Apr Mises à jour sur le test pour le coronavirus et date de publication des résultats

Posted at 07:09h in Novacyt Group

Paris, France et Camberley, Royaume-Uni – 29 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur son test d'amplification...

Read More

29 Apr Coronavirus test update and notification of final results

Posted at 07:07h in Board, Novacyt Group, Products

Paris, France and Camberley, UK – 29 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction...

Read More

27 Apr Contrat avec le Ministère de la Santé et des Affaires Sociales britannique pour la fourniture de tests COVID-19

Posted at 07:04h in Board, Novacyt Group, Products

Paris, France et Camberley, Royaume-Uni – 27 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir signé un contrat d’approvisionnement avec...

Read More

27 Apr Contract with UK Department of Health and Social Care for supply of COVID-19 tests

Posted at 07:01h in Board, Novacyt Group, Products

Paris, France and Camberley, UK – 27 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a supply contract with...

Read More

15 Apr Point sur la production et la R&D du test COVID-19

Posted at 15:09h in Board, Novacyt Group, Products

Paris, France et Camberley, Royaume-Uni – 15 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur la production, la...

Read More
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
Recent Posts
  • DHSC Claim update – Trial date listed

    30 January, 2023
  • Full Year 2022 Trading Update

    26 January, 2023
  • Holdings in Company

    06 January, 2023
  • Non-Executive Director Change

    07 December, 2022
  • Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation

    06 December, 2022
Archives
Categories

About


Novacyt is a leading global diagnostics company. We protect people and society in the fight against infectious diseases.

Company


York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG

Novacyt UK Holdings - 12031776
Novacyt SA - 491062527

Latest reports


Investor Presentation September 2022
Year in Review 2021

© 2022 Novacyt | Privacy Policy | Copyright | Terms & Conditions

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT